Skip to main content
13033 search results for:

Anthracycline 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 07-03-2024 | Trastuzumab | OriginalPaper

    Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

    Breast Cancer (BC) is the most prevalent cancer worldwide with 2.26 million cases in 2020 according to the World Health Organization (WHO). BC is a heterogeneous disease which encompasses a large number of molecular subtypes. The survival rates …

  2. Open Access 03-05-2024 | Anthracycline | OriginalPaper

    Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis

    Anthracycline antibiotic is one of the most effective anti-tumor drugs used to manage certain types of breast cancers, lymphomas, and leukemias. However, anthracyclines induce a dose-dependent cardiotoxicity that may progress to heart failure.

  3. Open Access 01-12-2024 | Anthracycline | OriginalPaper

    Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: a case control study

    Anthracyclines (AC) are one of the most commonly used chemotherapeutic agents, but they are associated with significant toxicities, with cardiotoxicity being the most concerning. Up to 57% of all patients receiving AC develop subclinical …

  4. 25-04-2024 | Anthracycline | Online First

    Evaluation the Effect of Anthracyclines on Cardiac Function in Children Lymphoma Survivors by Left Ventricular Myocardial Work

    Anthracycline chemotherapy is associated with the left ventricular (LV) dysfunction, but the conventional echocardiographic parameter is insensitive in detecting subclinical cardiac dysfunction, and the role of echocardiography in children cancer …

  5. Open Access 29-04-2024 | Anthracycline | Online First

    Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan

    Breast cancer is one of the most common malignancies in the world and the leading cause of cancer-related death among women [ 1 , 2 ]. Compared with other malignancies in Japanese women, breast cancer has the highest age-adjusted mortality rate …

  6. 01-03-2024 | Anthracycline | News

    Anthracyclines/cytarabine/hydroxycarbamide

    Lack of efficacy
  7. 01-03-2024 | Anthracycline | News

    Anthracyclines/cytarabine/tretinoin

    Lack of efficacy
  8. 16-03-2024 | Positron Emission Tomography | Online First

    Early detection of anthracycline-induced cardiotoxicity using [68 Ga]Ga-FAPI-04 imaging

    Chemotherapy remains the dominant first-line cancer treatment option in the clinic and anthracyclines are frequently used and highly effective chemotherapy drugs [ 1 , 2 ]. However, these chemotherapy drugs are toxic to numerous healthy cell types …

  9. Open Access 14-03-2024 | Anthracycline | Online First

    Characterization of anthracycline-induced cardiotoxicity by diffusion tensor magnetic resonance imaging

    Anthracyclines are highly potent anti-cancer drugs, but their clinical use is limited by severe cardiotoxic side effects. The impact of anthracycline-induced cardiotoxicity (AIC) on left ventricular (LV) microarchitecture and diffusion properties …

  10. 08-03-2024 | Anthracycline | Online First

    Obesity Predisposes Anthracycline-Treated Survivors of Childhood and Adolescent Cancers to Subclinical Cardiac Dysfunction

    Anthracyclines are effective chemotherapeutics used in approximately 60% of pediatric cancer cases but have a well-documented risk of cardiotoxicity. Existing cardiotoxicity risk calculators do not include cardiovascular risk factors present at …

  11. 12-02-2024 | Anthracycline | OriginalPaper

    Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 months of disease regression in a patient with breast cancer liver metastases resistant to multiple systemic chemotherapies

    Hepatic arterial infusion chemotherapy (HAIC) for liver metastases (LMs) from breast cancer is not a standard of care, but its effectiveness in patients with extensive LMs who cannot tolerate systemic therapy has been reported. Herein, we report a …

  12. 17-01-2024 | Adverse Effects of Cancer Therapy | News | Article

    Carvedilol does not mitigate anthracycline cardiotoxicity in childhood cancer survivors

    PREVENT-HF trial results do not support the use of low-dose carvedilol for heart failure risk reduction in anthracycline-exposed childhood cancer survivors.

  13. 08-02-2024 | Anthracycline | Online First

    Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors

    Osteosarcoma (OS) is a primary malignant tumor originating from mesenchymal tissue, predominantly occurring in the epiphysis of long bones. It is one of the most common cancers among children and adolescents, with a global annual incidence rate of …

  14. Open Access 01-12-2024 | Anthracycline | OriginalPaper

    Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study

    Mohammed VI University Hospital, Medical Oncology Department, Marrakech, Morocco

    Breast cancer (BC) is the most common cancer in women worldwide [ 1 ]. Aside population aging, rising BC rates are associated with increasing social and economic development and a more Westernized lifestyle (e.g., increased smoking, poor diet …

  15. 01-12-2023 | Anthracycline | News

    Cytarabine/unspecified anthracycline

    Heart-failure
  16. 03-02-2024 | Sarcoma | Online First

    Impact of anthracycline-based chemotherapy on RB1 gene methylation in peripheral blood leukocytes and biomarkers of oxidative stress and inflammation in sarcoma patients

    Sarcomas are a large, heterogeneous group of mesenchymal neoplasms comprising more than 100 distinct histological subtypes of varying degree of aggressiveness [ 1 , 2 ]. Based on origin/location, sarcomas can be divided into soft tissue sarcomas …

  17. Open Access 01-02-2024 | Soft Tissue Sarcoma | OriginalPaper

    Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy

    Soft tissue sarcomas (STS) are a large group of malignant mesenchymal tissue tumors and can occur in various parts of the body (Karakousis and Perez 1994 ). Although the incidence rate of soft tissue sarcoma accounts for only 1% of all solid …

  18. 10-01-2024 | Anthracycline | Letter

    Guidelines for Standardization of Pediatric Anthracycline Cardiomyopathy Echocardiogram Surveillance—A Call for Harmonization in the Field to Enhance Research in the Cancer Survivor Population

  19. 16-11-2023 | Anthracycline | OriginalPaper

    Assessment of anthracycline-induced cardiotoxicity in childhood cancer survivors during long-term follow-up using strain analysis and intraventricular pressure gradient measurements

    The mortality rate among patients with cancer has decreased over the past 3 decades owing to the development of anticancer drugs, such as anthracyclines, radiation therapy, and targeted therapies [ 1 , 2 ]. The management of cardiotoxicity by …

  20. Open Access 01-12-2023 | Cytostatic Therapy | OriginalPaper

    Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis

    Anthracycline-based chemotherapy is a common and effective treatment for various solid and hematologic malignancies, including breast, gynecologic, and bladder cancers, as well as leukemia and lymphoma [ 1 , 2 ]. Although effective, the use of …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.